Titre : | Potential for abuse of buprenorphine in office-based treatment of opioid dependence (2005) |
Auteurs : | T. J. CICERO ; J. A. INCIARDI |
Type de document : | Article : Périodique |
Dans : | New England Journal of Medicine (Vol.353, n°17, October 27, 2005) |
Article en page(s) : | 1863-1865 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés BUPRENORPHINE ; ABUS ; OPIACES ; TRAITEMENTThésaurus géographique ETATS-UNIS |
Résumé : | To the Editor: Buprenorphine was approved by the Food and Drug Administration (FDA) in 2002 for the treatment of opioid addiction in certified physicians' offices. However, the FDA and the Drug Enforcement Administration (DEA) expressed concern that the use of buprenorphine in opioid-dependent populations would inevitably lead to its diversion and abuse. Thus, buprenorphine was moved from Schedule V of the Controlled Substances Act to Schedule III. In an effort to restrict the number of persons exposed to the drug, a limit was imposed of no more than 30 patients per qualifying certified physician. |
Domaine : | Drogues illicites / Illicit drugs |
Affiliation : | Washington University, St. Louis, MO, USA |
Centre Emetteur : | 13 OFDT |
Lien : | http://dx.doi.org/10.1056/NEJM200510273531724 |
Accueil